Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2019-11-24 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
关于使用部分暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by Shanghai Medicilon Inc. regarding the use of temporarily idle raised funds for cash management. It details the board and supervisory committee meetings approving the use of up to RMB 494.9 million of idle raised funds to invest in secure, liquid financial products. The document references regulatory approvals, fundraising details, and compliance with listing rules and regulatory guidelines. It includes opinions from independent directors and the sponsor institution. The content is focused on the company's capital management activities related to raised funds, not a financial report or earnings release. It is a regulatory announcement about capital/financing activities, specifically the use of raised funds for cash management. The document length is about 5,428 characters, which is sufficient for a detailed announcement but not a full financial report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2019-11-24 Chinese
独立董事关于第二届董事会第八次会议相关事项的独立意见
Regulatory Filings
2019-11-24 Chinese
第二届监事会第七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a supervisory board meeting of Shanghai Medicilon Inc. It details the meeting date, attendance, and specific decisions regarding the use of temporarily idle raised funds for cash management and the replacement of self-raised funds with raised funds. The document references compliance with regulatory guidelines and provides voting results. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is an official announcement of board/management decisions related to fund usage, which fits best under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Therefore, the classification is MANG with high confidence.
2019-11-24 Chinese
广发证券股份有限公司关于上海美迪西生物医药股份有限公司使用部分闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from the sponsor (广发证券股份有限公司) regarding the use of part of the company's idle raised funds for cash management. It references regulatory guidelines related to the management and use of raised funds, details the investment products, amounts, risk controls, and approvals by the board and supervisory committee. It is not a general financial report like an annual or interim report, nor is it a brief announcement or voting result. It is a formal verification and opinion report by the sponsor on the company's compliance and use of raised funds, which fits the category of an Audit Report / Information (AR) as it involves verification and compliance review related to financial management but is not a full annual report or earnings release. The document length (4871 characters) and content confirm it is a substantive report rather than a short announcement or certification. Therefore, the best classification is AR (Audit Report / Information). FY 2019
2019-11-24 Chinese
广发证券股份有限公司关于上海美迪西生物医药股份有限公司使用募集资金置换预先投入的自筹资金的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from a sponsoring securities company regarding the use of raised funds to replace self-raised funds previously invested by the company. It references regulatory approvals, fundraising details, and audit reports related to the company's initial public offering and use of proceeds. The document is a formal verification or attestation related to the management and use of fundraising proceeds, including compliance with regulatory requirements and internal approvals. It does not contain comprehensive financial statements or detailed financial performance data typical of an Annual Report or Interim Report. It is also not a simple announcement or a brief summary but a detailed verification opinion by the sponsor and auditor. This type of document fits best under Regulatory Filings (RNS), as it is a compliance-related filing that does not constitute a full financial report or other specific report types defined in the taxonomy.
2019-11-24 Chinese
立信会计师事务所（特殊普通合伙）关于上海美迪西生物医药股份有限公司募集资金置换专项鉴证报告
Regulatory Filings
2019-11-24 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.